LFCR — Lifecore Biomedical Inc.

Lifecore Biomedical Inc. (LFCR) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Paul Josephs, based in 3515 Lyman Boulevard, Chaska, MN, United States, 55318, with about 382 employees. Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Net income was -$10.0M. LFCR currently screens at market cap $207.1M.

Use this LFCR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LFCR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LFCR SEC filings page. Lician reads the product cache first so this HTML stays unique to Lifecore Biomedical Inc. even when a live quote feed is slow.